Markets · 1 sources covering this

GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

GSK Plc is in discussions to purchase cancer treatment maker Nuvalent Inc. for between $9 billion and $10 billion, the Financial Times reported, citing unidentified people familiar with the matter.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·3h ago
GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT
GSK Plc is in discussions to purchase cancer treatment maker Nuvalent Inc. for between $9 billion and $10 billion, the Financial Times reported, citing unidentified people familiar with the matter.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/a5d12773c22fe206a6b6aabfa23a89558ee5626a"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT"></iframe>

GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

How 1 sources are covering this

GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT

More from Markets

Apple's Siri AI Has Upper Edge vs Rivals, IDC Says

Indonesia’s Five-Year Bond Yield Climbs to Highest Since 2020

China Coking Coal Slides After Report on Push to Maintain Output

Nifty Swings Rise as War Risk Unnerves India Stock Bulls

Reader

Trust & legal

Across the network